Isoquinolines (including Hydrogenated) Patents (Class 514/307)
  • Patent number: 10406199
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 10, 2019
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 10385024
    Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 20, 2019
    Assignee: ARDELYX, INC.
    Inventors: Noah Bell, Christopher Carreras, Dominique Charmot, Tao Chen, Michael Leadbetter, Jeffrey Jacobs, Jason Lewis
  • Patent number: 10385060
    Abstract: The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 20, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hangrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai Yu, Fanglong Yang, Lei Chen, Jingjing Yan, Xiqian Zhang, Zhichao Xie, Lingxiang Chen, Mingxun He
  • Patent number: 10385399
    Abstract: The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD11 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status 10 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: August 20, 2019
    Assignee: AARHUS UNIVERSITET
    Inventors: Jens Overgaard, Brita Singers Sorensen, Jan Alsner, Carsten Wiuf, Marianne Nordsmark, Kasper Toustrup
  • Patent number: 10376481
    Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: August 13, 2019
    Assignee: ARDELYX, INC.
    Inventors: Noah Bell, Christopher Carreras, Michael Robert Leadbetter, Jason Gustaf Lewis, Jeffrey W. Jacobs, Irina Dotsenko, Dean Dragoli, Ying He, Andrew King, Matthew Siegel
  • Patent number: 10329516
    Abstract: The present invention relates to novel compounds and their use as fragrance materials.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: June 25, 2019
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Benjamin Amorelli, Iyare Amegor, Michael G. Monteleone, Vincent Colandrea
  • Patent number: 10316029
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 11, 2019
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill M. Sturdivant, Susan M. Royalty
  • Patent number: 10292980
    Abstract: In DN-DISC1 mice, a mouse model for major mental illnesses, the model that expresses pathological phenotypes relevant to schizophrenia, mood disorders, and addiction simultaneously, the inventors of the present invention found pronounced levels of oxidative stress in the prefrontal cortex, but not in the striatum. These mice also displayed greater amounts of GAPDH-Siah1 binding, a protein-protein interaction that is activated under exposure to oxidative stress. The present inventors investigated the role of oxidative stress in other organ systems. As detailed herein, the inventors found that GAPDH-Siah1 binding was increased in mouse models of cardiac failure. It was also found, that certain novel analogs of deprenyl, significantly inhibited GAPDH-Siah1 binding in cardiac tissue.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: May 21, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Akira Sawa, Elki Takimoto, Neelam Shahani, David Kass, Toshiaki Saito
  • Patent number: 10247737
    Abstract: A method of classifying a subject having idiopathic scoliosis (IS) or at risk of developing IS comprising: determining the cellular response to Gi stimulation in a cell sample from the subject in the presence of OPN; determining the cellular response to Gi stimulation in a cell sample from the subject in the absence of OPN; and comparing the cellular response obtained in the presence of OPN with the cellular response obtained in the absence of OPN, whereby the comparing step enables the classification of the subject into one IS functional group. Also provided is the use of the foregoing method to classify borderline subjects and kits for applying the methods.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: April 2, 2019
    Assignee: Chu Sainte-Justine
    Inventors: Alain Moreau, Marie-Yvonne Akoume Ndong
  • Patent number: 10195192
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: February 5, 2019
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • Patent number: 10174017
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: January 8, 2019
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill M. Sturdivant, Susan M. Royalty
  • Patent number: 10159634
    Abstract: A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: December 25, 2018
    Inventors: Mitchell A. deLong, Elise A. Olsen
  • Patent number: 10123997
    Abstract: A method of treating hepatitis B virus includes inhibiting the activities of AKT and/or mTOR, inhibiting the synthesis of 5-phosphate ribose, and inhibiting HBV DNA and HBV cccDNA.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: November 13, 2018
    Inventor: Yong Liao
  • Patent number: 10081607
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a 2,4-diaminoquinazoline compound, pharmaceutical compositions including a 2,4-diaminoquinazoline compound, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: September 25, 2018
    Assignee: University of South Florida
    Inventors: Roman Manetsch, Lindsey Neil Shaw, Kurt Steven Van Horn, Whittney Nicole Burda
  • Patent number: 10077261
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 18, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J. Connolly, Gilles C. Bignan, Tianbao Lu, Michael H. Parker, Donald W. Ludovici, Christophe Meyer, Lieven Meerpoel, Karine Smans, Christian Rocaboy
  • Patent number: 10047087
    Abstract: The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 14, 2018
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Pradip Kumar Sasmal, Shahadat Ahmed, Ashok Tehim, Vidyadhar Paradkar, Prasanna M. Dattatreya, Nanjegowda Jagadeesh Mavinahalli
  • Patent number: 9993470
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: June 12, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Patent number: 9963432
    Abstract: Disclosed are alpha-aryl-beta-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing isoquinoline amide compounds.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 8, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Jill M. Sturdivant, Mitchell A. deLong, Susan M. Royalty
  • Patent number: 9951059
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 24, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Patent number: 9856239
    Abstract: The present invention relates to the technical field of medicine, and specifically relates to the carboxylic acid compound represented by the chemical formula I or chemical formula II, and a pharmaceutically acceptable salt, a prodrug, and a solvate thereof, and a method for preparation thereof, as well as a pharmaceutical composition containing the described substances, and a use thereof.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: January 2, 2018
    Assignee: InventisBio Shanghai Ltd.
    Inventor: Yueheng Jiang
  • Patent number: 9856478
    Abstract: The present invention features methods for preventing and treating three related diseases, diet-induced obesity, metabolic syndrome, and atherosclerosis, alone or in combination by inhibiting Acyl-CoA:Cholesterol Acyltransferase 1 (ACATI) activity or expression in myeloid cells.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: January 2, 2018
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Ta-Yuan Chang, Catherine C. Y. Chang, Li-Hao Huang, Elaina Melton, Paul Sohn
  • Patent number: 9814751
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: November 14, 2017
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 9815797
    Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: November 14, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Rikki Peter Alexander, Gregory Foulkes, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, James Thomas Reuberson, Sarah Margaret Rook, Zhaoning Zhu
  • Patent number: 9809858
    Abstract: Biomarkers, methods, assays, and kits are provided for determining the prognosis of and treating a patient with ovarian cancer. Also disclosed are biomarkers, methods, assays, and kits for predicting the sensitivity of ovarian cancer cells to chemotherapy.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: November 7, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
  • Patent number: 9791452
    Abstract: This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTNFR1, sTNFR2, sFAS, TNF, and IL-6.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: October 17, 2017
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Monika A. Niewczas, Andrzej S. Krolewski
  • Patent number: 9783573
    Abstract: There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: October 10, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Kyoung S. Kim, Heidi L. Perez, Erik M. Stang, David K. Williams, Liping Zhang
  • Patent number: 9783544
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 10, 2017
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 9775902
    Abstract: The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: October 3, 2017
    Assignee: FIBROGEN, INC
    Inventors: Stephen J. Klaus, Ingrid Langsetmo Parobok, Christopher T. Jacob
  • Patent number: 9751850
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: September 5, 2017
    Assignee: ABBVIE INC.
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • Patent number: 9707222
    Abstract: The present invention provides a method for activating the AMP-dependent protein kinase (AMPK) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol or reticuline. The pharmaceutical composition is able to activate AMPK, and thus is effective in the regulation of cell growth and metabolism, and the treatment of AMPK associated diseases.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: July 18, 2017
    Assignee: ZIH YUAN TANG BIOTECHNOLOGY CO., LTD.
    Inventors: Shoei-Sheng Lee, Ming-Jai Su, Chi-Huan Yeh, Sheng-Fa Tsai, Cheng-Yen Tsai, Chi-Tun Ruan, Chao-Min Hsu
  • Patent number: 9688635
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: June 27, 2017
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-liang Zhu
  • Patent number: 9682950
    Abstract: Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: June 20, 2017
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, He Huang, Qing Jing
  • Patent number: 9643927
    Abstract: Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 9, 2017
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Jill M. Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
  • Patent number: 9636338
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 2, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Robert Britton, Benoit Hornsperger, Bernd Kuhn, Hans P. Maerki, Rainer E. Martin, Alexander V. Mayweg, Xuefei Tan
  • Patent number: 9636339
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 2, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Robert Britton, Benoit Hornsperger, Bernd Kuhn, Hans P. Maerki, Rainer E. Martin, Alexander V. Mayweg, Xuefei Tan
  • Patent number: 9630936
    Abstract: The present disclosure provides pharmaceutical compositions comprising Gamma-glutamyl cycle inhibitors (GGCI) and certain pharmaceutically acceptable salts thereof, and methods of use.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: April 25, 2017
    Assignee: Cancer Research Technology, LLC
    Inventors: David Rubin, Eyal Rubin
  • Patent number: 9610275
    Abstract: Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: April 4, 2017
    Assignee: Cellceutix Corporation
    Inventors: Krishna Menon, Wayne O. Aruda
  • Patent number: 9604960
    Abstract: Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: March 28, 2017
    Assignee: Albany Molecular Research, Inc.
    Inventors: Shuang Liu, Bruce F. Molino, Kassoum Nacro
  • Patent number: 9597314
    Abstract: 0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more ?-lactamyl alkanoic acids are also described.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: March 21, 2017
    Assignee: AZEVAN PHARMACEUTICALS, INC.
    Inventors: Gary A. Koppel, Marvin J. Miller
  • Patent number: 9560764
    Abstract: A chip-component structure includes an interposer on which a multilayer capacitor is mounted. The interposer includes component connecting electrodes, external connection electrodes, side electrodes, and in-hole electrodes. The component connecting electrodes and the external connection electrodes are electrically connected by the side electrodes and the in-hole electrodes. Outer electrodes of the capacitor are joined to the component connecting electrodes.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: January 31, 2017
    Assignee: Murata Manufacturing Co., Ltd.
    Inventors: Kazuo Hattori, Isamu Fujimoto
  • Patent number: 9511161
    Abstract: The present invention relates to methods for reducing the population of (e.g., killing) arthropods employing compositions including medium chain peroxycarboxylic acid, and to the compositions. The methods include applying a medium chain peroxycarboxylic acid composition to an arthropod or a surface or area suspected of housing an arthropod.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: December 6, 2016
    Assignee: Ecolab USA Inc.
    Inventors: Emory H. Matts, Victor Fuk-Pong Man, Joshua P. Magnuson, S. John Barcay, James J. Tarara, Thomas D. Nelson
  • Patent number: 9463183
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 11, 2016
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 9447077
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: September 20, 2016
    Assignee: SARcode Bioscience Inc.
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • Patent number: 9353048
    Abstract: The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: May 31, 2016
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Fei Chen, Yangming Zhang, Pingzheng Zhou, Haining Hu, Haiyan Xu, Sheng Liu
  • Patent number: 9353088
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: May 31, 2016
    Assignee: SARcode Bioscience Inc.
    Inventor: John Burnier
  • Patent number: 9340491
    Abstract: Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: May 17, 2016
    Assignee: Cellceutix Corporation
    Inventor: Krishna Menon
  • Patent number: 9288986
    Abstract: This is to provide a plant disease control composition having a broad spectrum against various plant pathogens, and shows excellent controlling effects (synergistic controlling effects) which cannot be expected from a single component alone. A plant disease control composition comprising (Group a) at least one quinoline compound represented by the formula: (wherein R1, R2: an alkyl which may be substituted, an aryl which may be substituted, etc.; R3, R4: H, an alkyl which may be substituted, etc.; X: halogen, an alkyl which may be substituted, etc.; Y: halogen, alkyl, etc.; n: 0 to 4; m: 0 to 6) or a salt thereof, and at least one of fungicidal compounds selected from the group consisting of a Strobilurin series compound, a triazole series compound, etc., as effective ingredients.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: March 22, 2016
    Assignee: MITSUI CHEMICALS AGRO, INC.
    Inventors: Yasushi Tamagawa, Hiroshi Ishimoto, Mayumi Takagi, Toshiaki Ohara, Harukazu Tanaka
  • Patent number: 9271959
    Abstract: The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 1, 2016
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Miguel Angel Pericas-Brondo, Antonio Torrens-Jover, Susana Yenes-Minguez, Felix Cuevas Cordobes, Carmen Garcia Granda
  • Patent number: 9266855
    Abstract: The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: February 23, 2016
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Sean Colm Turner, Margaretha Henrica Maria Bakker, Marcel Van Gaalen, Falko Ernst Wolter, Wilfried Hornberger, Marjoleen Nijsen
  • Patent number: RE46886
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 5, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John Ginn, Michael D. Lowe, Christopher Ronald Sarko, Edward S. Tasber, Zhonghua Zhang